Please login to the form below

Not currently logged in
Email:
Password:

GW Pharma appoints Julian Gangolli as North American president

Appointment coincides with GW Pharma’s US launch

edit-GW-julian-gangolliBiopharma company GW Pharma has named Julian Gangolli as its president for North America.

GW Pharma is also relocating its CEO, Justin Glover, to the US to support its imminent launch in the States.

Commenting on his appointment, Gangolli said: “I wish to bring my experience of building a successful business for Allergan to GW and look forward to working with Justin and the entire GW team to optimise the Company's prospects in this key market.”

Gangolli was president of the North American pharma division of Allergan for from 2004 until April of this year, overseeing a 1,400 person commercial operation. 

As president, Gangolli's responsibilities included four business units supporting ophthalmology and optometry, neurosciences, urology and medical dermatology for the US and Canada. 

He was additionally responsible for strategic planning, business development, research and product development planning for the North American division.

Geoffrey Guy, GW Pharma's chairman, added: “Julian's deep experience at building and running a major US pharmaceutical business built on specialty products will be complemented by the relocation of Justin to the US with his intimate knowledge of GW, its products and pipeline. 

“Together, they will spearhead GW's growth in the U.S. and help to bring much needed new treatments to patients.”

17th June 2015

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...
Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...

Infographics